PubMed Health⌕ Search

PubMed · 16725576

Corpus luteum function in ewes stimulated by rams.

Abstract

In late February Dorset rams were introduced (day = 0) to 40 mature Romney ewes that were observed by laparoscopy to be anovular. The ovaries of 20 of these ewes were examined by laparoscopy every second day while the remaining 20 ewes served as unoperated controls. Jugular blood samples were taken daily and plasma progesterone concentrations assayed to provide information on the functional status of any corpora lutea (CL) arising from ovulations stimulated by introduction of the rams. Eighty-five percent (17/20) of the ewes that were repeatedly laparoscoped had ovulated within 4 days of ram introduction and premature regression of the CL had occurred between days 4 and 8 in 8 ewes and days 6 to 10 in 2 ewes. A second ovulation was observed after or during the premature regression of the first CL and this subsequent CL was maintained for the normal duration. The prematurely regressing CL produced a small peak in progesterone concentration on days 4 to 5 but the concentrations declined on days 6 to 7. In the unoperated ewes 50% (10/20) appeared, from the progesterone profiles, to have ovulated by day 4 and half of these appeared to have premature CL regression. The interval from introduction of the ram to first oestrus was 23 days in ewes with premature regression of the CL and 19 days in ewes ovulating within 4 days but having no premature regression. From the results it was concluded that the premature regression of the CL is the cause of the delayed interval from ram introduction to first oestrus in Romney ewes and is a major factor contributing to the two peaks of oestrous activity observed after ram introduction.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

T W Knight, H R Tervit, R J Fairclough. 1981. Corpus luteum function in ewes stimulated by rams.. https://doi.org/10.1016/s0093-691x(81)80006-4

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗